Merus N.V. logo

Merus N.V.

NASDAQ:MRUS

Overview | Financials
Company Name Merus N.V.
Symbol MRUS
Currency USD
Price 56.66
Market Cap 3,753,022,416
Dividend Yield 0%
52-week-range 19.805 - 61.61
Industry Biotechnology
Sector Healthcare
CEO Dr. Sven Ante Lundberg M.D.
Website https://www.merus.nl

An error occurred while fetching data.

About Merus N.V.

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2

Related Stocks

Verve Therapeutics, Inc. logo

Verve Therapeutics, Inc.

VERV

5.59 USD

Nektar Therapeutics logo

Nektar Therapeutics

NKTR

1.29 USD

Codexis, Inc. logo

Codexis, Inc.

CDXS

3.3 USD

Avidity Biosciences, Inc. logo

Avidity Biosciences, Inc.

RNA

38.36 USD

Evolus, Inc. logo

Evolus, Inc.

EOLS

11.53 USD

Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc.

RCKT

22.73 USD

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.

TOI

0.532 USD

HealthStream, Inc. logo

HealthStream, Inc.

HSTM

28.13 USD

Financials

Numbers are in millions USD

Numbers are in millions USD